• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dynamic frailty-tailored therapy (DynaFiT): A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma.

作者信息

Dai Yun, Jin Fengyan

机构信息

Laboratory of Cancer Precision Medicine, the First Hospital of Jilin University, Changchun, Jilin, China.

Department of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Blood Sci. 2024 Oct 1;6(4):e00208. doi: 10.1097/BS9.0000000000000208. eCollection 2024 Oct.

DOI:10.1097/BS9.0000000000000208
PMID:39360310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11446587/
Abstract
摘要

相似文献

1
Dynamic frailty-tailored therapy (DynaFiT): A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma.动态衰弱个体化治疗（DynaFiT）：一项针对新诊断多发性骨髓瘤老年患者的概念验证研究。
Blood Sci. 2024 Oct 1;6(4):e00208. doi: 10.1097/BS9.0000000000000208. eCollection 2024 Oct.
2
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.老年初诊多发性骨髓瘤患者的个体化动态脆弱性定制治疗（DynaFiT）：一项前瞻性研究。
J Hematol Oncol. 2024 Jun 24;17(1):48. doi: 10.1186/s13045-024-01569-y.
3
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.根据新的基于虚弱的预后预测模型（Myeloma Risk Profile-MRP）评估英国真实世界老年初诊骨髓瘤患者的虚弱特征和临床结局。
PLoS One. 2022 Jan 11;17(1):e0262388. doi: 10.1371/journal.pone.0262388. eCollection 2022.
4
A comparison of three different approaches to defining frailty in older patients with multiple myeloma.三种不同方法用于定义老年多发性骨髓瘤患者虚弱状态的比较。
J Geriatr Oncol. 2020 Mar;11(2):311-315. doi: 10.1016/j.jgo.2019.07.004. Epub 2019 Jul 17.
5
Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.新诊断多发性骨髓瘤患者衰弱评分的比较：一项综述
J Frailty Aging. 2019;8(4):215-221. doi: 10.14283/jfa.2019.25.
6
Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma.医疗保险健康结果调查累积缺陷衰弱指数的开发及其在新诊断的多发性骨髓瘤老年患者中的应用。
JCO Clin Cancer Inform. 2018;2. doi: 10.1200/CCI.18.00043. Epub 2018 Jul 25.
7
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).真实世界多发性骨髓瘤患者老年综合征和衰弱分类的流行情况：一项前瞻性队列研究（MFRAIL）。
Leuk Lymphoma. 2024 Aug;65(8):1167-1174. doi: 10.1080/10428194.2024.2340052. Epub 2024 Apr 16.
8
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).虚弱降低了老年骨髓瘤患者诱导治疗的可行性，但不影响维持治疗：德国维持研究（GERMAIN）的最终结果。
J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2.
9
SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma.SOHO 最新进展及待解决问题：多发性骨髓瘤老年体弱患者的治疗。
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):279-286. doi: 10.1016/j.clml.2021.11.003. Epub 2021 Nov 11.
10
Management of Newly Diagnosed Elderly Multiple Myeloma Patients.初诊老年多发性骨髓瘤患者的管理。
Curr Oncol Rep. 2019 May 24;21(7):64. doi: 10.1007/s11912-019-0804-4.

引用本文的文献

1
The dynamic nature of frailty in metastatic spine disease patients.转移性脊柱疾病患者虚弱状态的动态本质。
J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05213-8.
2
The cross-sectional relationship of physical frailty and cognitive impairment in older Poles: analysis of the PolSenior2 data.波兰老年人身体虚弱与认知障碍的横断面关系：对PolSenior2数据的分析
Eur Geriatr Med. 2025 May 17. doi: 10.1007/s41999-025-01220-0.

本文引用的文献

1
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.老年初诊多发性骨髓瘤患者的个体化动态脆弱性定制治疗（DynaFiT）：一项前瞻性研究。
J Hematol Oncol. 2024 Jun 24;17(1):48. doi: 10.1186/s13045-024-01569-y.
2
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010).皮下注射达雷妥尤单抗治疗中国复发或难治性多发性骨髓瘤患者：一项开放标签、多中心、1期研究（MMY1010）。
Blood Sci. 2024 May 31;6(3):e00193. doi: 10.1097/BS9.0000000000000193. eCollection 2024 Jul.
3
Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.基于伊沙佐米的一线治疗，随后对新诊断的体弱老年多发性骨髓瘤患者进行伊沙佐米维持治疗：一项前瞻性多中心研究。
EClinicalMedicine. 2024 Jan 25;68:102431. doi: 10.1016/j.eclinm.2024.102431. eCollection 2024 Feb.
4
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.来那度胺预处理的多发性骨髓瘤患者中硼替佐米、泊马度胺和地塞米松治疗：根据脆弱性和硼替佐米剂量调整对 OPTIMISMM 的亚分析。
Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):165-176.e4. doi: 10.1016/j.clml.2023.10.009. Epub 2023 Nov 8.
5
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.伊沙佐米、达雷妥尤单抗与低剂量地塞米松用于初诊多发性骨髓瘤身体状况中等患者：一项开放标签的2期试验
EClinicalMedicine. 2023 Aug 29;63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep.
6
railty-adjusted therapy n ransplant on-ligible patient with newly diagnoed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.适合新诊断多发性骨髓瘤（FiTNEss（英国-MRA 骨髓瘤 XIV 试验））的移植不合格患者的风险调整治疗：一项随机 III 期试验的研究方案。
BMJ Open. 2022 Jun 2;12(6):e056147. doi: 10.1136/bmjopen-2021-056147.
7
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.达雷妥尤单抗联合来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤：MAIA 研究脆弱亚组分析。
Leukemia. 2022 Apr;36(4):1066-1077. doi: 10.1038/s41375-021-01488-8. Epub 2022 Jan 2.
8
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松与硼替佐米、美法仑和泼尼松在不适合移植的新诊断多发性骨髓瘤中的应用：ALCYONE 研究体弱亚组分析。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):785-798. doi: 10.1016/j.clml.2021.06.005. Epub 2021 Jun 18.
9
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.来那度胺、达雷妥尤单抗联合低剂量地塞米松治疗新诊断的 frail 多发性骨髓瘤患者：HOVON 143 研究。
J Clin Oncol. 2021 Sep 1;39(25):2758-2767. doi: 10.1200/JCO.20.03143. Epub 2021 May 4.
10
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.剂量/方案调整的 Rd-R 与连续 Rd 用于新诊断的老年、中危适合的多发性骨髓瘤患者。
Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.